Stability, toxicity and biological activity of retro, inversed and retro-inversed glucagon isomers

Journal of Peptide Science

Volumn 18, Issue 8, 2012, Pages 519-526

  Krasniqi, Besnik ^a   Scruten, Erin ^b   Piller, Jaret ^a   Lee, Jeremy ^a   Napper, Scott ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Inversion; Nanopore analysis and glucagon; Peptide modification; Retro; Retro inversion

Indexed keywords

GLUCAGON; GLUCOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CELL VIABILITY; CHEMICAL STRUCTURE; CIRCULAR DICHROISM; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOLYSIS; IN VIVO STUDY; ISOMER; MOLECULAR INTERACTION; MOLECULAR STABILITY; MOUSE; NANOPORE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN MODIFICATION;

ANIMALS; CATTLE; CELLS, CULTURED; CIRCULAR DICHROISM; FEMALE; GLUCAGON; HEMOLYSIS; ISOMERISM; MICE; MICE, INBRED BALB C; PEPTIDES;

MUS;

EID: 84864023027     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2429     Document Type: Article

References (31)

1. Werle M, Bernkop-Schnurch A. Strategies to improve plasma half life time of peptide and protein drugs. Amino Acids 2006; 30: 351-367.
2. Salhanick AI, Clairmont KB, Buckholz TM, Pellegrino CM, Ha S, Lumb KJ. Contribution of site-specific PEGylation to the dipeptidyl peptidase IV stability of glucose-dependent insulinotropic polypeptide. Bioorg. Med. Chem. Lett. 2005; 15: 4114-4117.
3. Su CM, Jensen LR, Heimer EP, Felix AM, Pan YC, Mowles TF. In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma. Horm. Metab. Res. 1991; 23: 15-21.
4. Powell MF, Stewart T, Otvos L, Jr., Gaeta FC, Sette A, Arrhenius T, Thomson D, Soda K, Colon SM. Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm. Res. 1993; 10: 1268-1273.
5. Osapay G, Prokai L, Kim HS, Medzihradszky KF, Coy DH, Liapakis G, Reisine T, Melacini G, Zhu Q, Wang SH, Mattern RH, Goodman M. Lanthionine-somatostatin analogs: synthesis, characterization, biological activity, and enzymatic stability studies. J. Med. Chem. 1997; 40: 2241-2251.
6. Brinckerhoff LH, Kalashnikov VV, Thompson LW, Yamshchikov GV, Pierce RA, Galavotti HS, Engelhard VH, Slingluff CL, Jr. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: implications for peptide vaccines. Int. J. Cancer 1999; 83: 326-334.
7. Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O'Harte FP, Flatt PR. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J. Endocrinol. 2004; 180: 379-388.
8. Fauchere JL, Thurieau C. Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design. Adv. Drug Res. 1992; 23: 127-159.
9. Bartnes K, Hannestad K, Guichard G, Briand JP. A retro-inverso analog mimics the cognate peptide epitope of a CD4+ T cell clone. Eur. J. Immunol. 1997; 27: 1387-1391.
10. Kindrachuk J, Scruten E, Attah-Poku S, Bell K, Potter A, Babiuk LA, Griebel PJ, Napper S. Stability, toxicity, and biological activity of host defense peptide BMAP28 and its inversed and retro-inversed isomers. Biopolymers 2011; 96: 14-24.
11. Taylor EM, Otero DA, Banks WA, O'Brien JS. Retro-inverso prosaptide peptides retain bioactivity, are stable in vivo, and are blood-brain barrier permeable. J. Pharmacol. Exp. Ther. 2000; 295: 190-194.
12. Kindrachuk J, Napper S. Structure-activity relationships of multifunctional host defence peptides. Mini Rev. Med. Chem. 2010; 10: 596-614.
13. Fischer PM. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr. Protein Pept. Sci. 2003; 4: 339-356.
14. Goodman M, Chorev M. On the concept of linear modified retro-peptide structures. Accounts Chem. Res. 1979; 12: 1-7.
15. Briand J-P, Guichard G, Dumortier H, Muller S. Retro-inverso peptidomimetics as new immunological probes. J. Biol. Chem. 1995; 270: 20686-20691.
16. Lee YS, Agnes RS, Davis P, Ma S-w, Badghisi H, Lai J, Porreca F, Hruby VJ. Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J. Med. Chem. 2006; 50: 165-168.
17. Sasaki K, Dockerill S, Adamiak DA, Tickle IJ, Blundell T. X-ray analysis of glucagon and its relationship to receptor binding. Nature 1975; 257: 751-757.
18. Unson CG. Molecular determinants of glucagon receptor signaling. Biopolymers Pept. Sci. 2002; 66: 218-235.
19. Unson CG, Merrifield RB. Identification of an essential serine residue in glucagon: implication for an active site triad. Proc. Natl. Acad. Sci. U. S. A. 1994; 91: 454-458.
20. Unson C, Gurzenda E, Iwasa K, Merrifield R. Glucagon antagonists: contribution to binding and activity of the amino- terminal sequence 1-5, position 12, and the putative alpha-helical segment 19-27. J. Biol. Chem. 1989; 264: 789-794.
21. Stefureac R, Long Y-T, Kraatz H-B, Howard P, Lee JS. Transport of alpha-helical peptides through alpha-hemolysin and aerolysin pores. Biochemistry 2006; 45: 9172-9179.
22. Christensen C, Baran C, Krasniqi B, Stefureac RI, Nokhrin S, Lee JS. Effect of charge, topology and orientation of the electric field on the interaction of peptides with the α-hemolysin pore. J. Pept. Sci. 2011; 17: 726-734.
23. Meng H, Detillieux D, Baran C, Krasniqi B, Christensen C, Madampage C, Stefureac RI, Lee JS. Nanopore analysis of tethered peptides. J. Pept. Sci. 2010; 16: 701-708.
24. Kaushik RS, Begg AA, Wilson HL, Aich P, Abrahamsen MS, Potter A, Babiuk LA, Griebel P. Establishment of fetal bovine intestinal epithelial cell cultures susceptible to bovine rotavirus infection. J. Virol. Methods 2008; 148: 182-196.
25. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 1997; 27: 1-20.
26. Jaspan JB, Polonsky KS, Lewis M, Pensler J, Pugh W, Moossa AR, Rubenstein AH. Hepatic metabolism of glucagon in the dog: contribution of the liver to overall metabolic disposal of glucagon. Am. J. Physiol. 1981; 240: E233-E244.
27. Alford FP, Bloom SR, Nabarro JDN. Glucagon metabolism in man. Studies on the metabolic clearance rate and the plasma acute disappearance time of glucagon in normal and diabetic subjects. J. Clin. Endocrinol. Metab. 1976; 42: 830-838.
28. Hinke SA, Pospisilik JA, Demuth H-U, Mannhart S, Kühn-Wache K, Hoffmann T, Nishimura E, Pederson RA, McIntosh CHS. Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. J. Biol. Chem. 2000; 275: 3827-3834.
29. Gerber D, Quintana FJ, Bloch I, Cohen IR, Shai Y. D-enantiomer peptide of the TCRα transmembrane domain inhibits T-cell activation in vitro and in vivo. FASEB J. 2005; 19: 1190-1192.
30. Stefureac R, Waldner L, Howard P, Lee JS. Nanopore analysis of a small 86-residue protein. Small 2008; 4: 59-63.
31. Scruten E, Kovacs-Nolan J, Griebel PJ, Latimer L, Kindrachuk J, Potter A, Babiuk LA, Littel-van den Hurk SD, Napper S. Retro-inversion enhances the adjuvant and CpG co-adjuvant activity of host defence peptide Bac2A. Vaccine 2010; 28: 2945-2956.